Cash Tender Offer - Pricing, Expiration and Result

Summary by AI BETAClose X

Haleon plc has announced the pricing, expiration, and results of its cash tender offer for all outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027, issued by its wholly owned subsidiary Haleon US Capital LLC. This action indicates a proactive approach to managing its debt obligations.

Disclaimer*

Haleon PLC
19 August 2026
 

 

 

Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

 

Note: This announcement is being released in accordance with DTR 6.3.10 R. In the United Kingdom, the Tender Offer was only available to relevant persons, as described under "Non-U.S. Distribution Restrictions - United Kingdom" in the tender offer announcement available at https://www.rns-pdf.londonstockexchange.com/rns/2411Q_1-2026-8-11.pdf.

 

19 August 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer").

 

The full announcement is available at http://www.rns-pdf.londonstockexchange.com/rns/3204R_1-2026-8-19.pdf.

 

The full announcement will also be available on the Haleon website www.haleon.com/investors, and has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries

 

Investors

Media

 

Jo Russell

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Victoria Durman

+44 7894 505730

 

Email: investor-relations@haleon.com

 

Email: corporate.media@haleon.com



Treasury


Mike Rowe

+44 7775 012365


Ben Checkland

+44 7823 370368


 

Email: cf-treasury@haleon.com


 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Haleon (HLN)
UK 100